Trials
4 active
10 in total · 9 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “GNR-139 is being developed as a biosimilar to the reference medicinal product Eylea®”In the company’s words, NCT07844148 on ClinicalTrials.gov
- Tested for
- nAMD
- Main trialPhase 3
- “This is a multicenter, randomized, double-blind study designed to compare the efficacy and safety of the investigational drug GNR-139 with the reference drug Eylea in treatment-naive patients with neovascular age-related macular degeneration (nAMD). Participants will be randomly assigned to receive either GNR-139 or Eylea. Neither the participants nor the study doctors will know which treatment is being administered. Both drugs will be given as an intravitreal injection dose of 8 mg (0.07 mL at a concentration of 114.3 mg/mL). Patients meeting the eligibility criteria will be randomised in…”In the company’s words, NCT07844148 on ClinicalTrials.gov
- Other names
- aflibercept
- Copy of
- Eylea (Regeneron Pharmaceuticals)Tested side by side with the original in NCT07844148
Other drugs for nAMD
- Surabgene LomparvovecAbbVie · Phase 3
- TiespectusEyeBiotech Ltd. · Phase 2/3
- VIS-101Everest Medicines (China) Co.,Ltd. · Phase 2
Coming up1
- May 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | May 2028 | A Study to Compare GNR-139 and Eylea® in Patients With nAMD | |
| Phase 3Ended | not given | Single-arm, open label, multicenter clinical study to evaluate the handling and safety of AVT06 pre-filled syringe (PFS) in subjects with chorioretinal vascular disease followed by an optional extension phase of AVT06 pre-filled syringe (PFS). | |
| Phase 3Ended | not given | TELeMAC - Comparative multicenter randomized study of aflibercept versus placebo in macular telangiectasia type 1 | |
| Phase 3Ended | not given | An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study | |
| Phase 3Ended | not given | Neovascular glaucoma prevention by intravitreal injections of anti-VEGF in patients treated by protontherapy in case of large choroid melanoma | |
| Phase 3/4Ended | not given | Aflibercept 8mg for high-frequent Faricimab and prior Aflibercept 2mg treated Neovascular age-related macular degeneration: a monocenter, single-arm, open-label extension study (A-FAN) | |
| Phase 2Ended | not given | Spontaneous Retinal Arterial Pulsations (SRAPs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVOs) in patients treated or not with intravitreal injections of aflibercept | |
| Phase 4Authorised | not given | Personalized treatment aided by automated analysis of fluid in active neovascular age-related macular degeneration (nAMD) in a prospective, multicenter, randomized study | |
| Phase 2Authorised | not given | Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2 | |
| Phase 4Authorised | not given | Two initial aflibercept 8 mg loading doses in treatment-naive neovascular AMD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026